Vasculitis
MONDO:0018882Vasculitis represents a clinically heterogenous group of diseases of multifactorial etiology characterized by inflammation of either large-sized vessels (large-vessel vasculitis, e.g. Giant-cell arteritis and Takayasu arteritis), medium-sized vessels (medium-vessel vasculitis e.g. polyarteritis nodosa and Kawasaki disease), or small-sized vessels (small-vessel vasculitis, e.g. granulomatosis with polyangiitis, microscopic polyangiitis, immunoglobulin A vasculitis, and cutaneous leukocytoclastic angiitis). Vasculitis occurs at any age, may be acute or chronic, and manifests with general symptoms such as fever, weight loss and fatigue, as well as more specific clinical signs depending on the type of vessels and organs affected. The degree of severity is variable, ranging from life or sight threatening disease (e.g. Behcet disease) to relatively minor skin disease.
Also known as: systemic vasculitis, angiitis
286 clinical trials for this condition and its sub-types, 63 tagged with Vasculitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Vasculitis
-
Necrotizing vasculitis 0 trials · 143 incl. sub-types
3 sub-types
- Anti-neutrophil cytoplasmic antibody-associated vasculitis 82 trials · 130 incl. sub-types Sub-types →
- Immunoglobulin A vasculitis 16 trials
- Disseminated visceral giant cell angiitis 0 trials
-
Arteritis 5 trials · 104 incl. sub-types
7 sub-types
- Granulomatous angiitis 0 trials · 52 incl. sub-types Sub-types →
- Microscopic polyangiitis 34 trials
- Takayasu arteritis 27 trials
- Polyarteritis nodosa 7 trials · 9 incl. sub-types Sub-types →
- Cerebral arteritis 0 trials
- Endarteritis 0 trials
- Juvenile temporal arteritis 0 trials
-
Central nervous system vasculitis 3 trials · 55 incl. sub-types
5 sub-types
- Temporal arteritis 52 trials Sub-types →
- Primary central nervous system vasculitis 2 trials Sub-types →
- Benign angiitis of the central nervous system 0 trials
- Central nervous system AIDS arteritis 0 trials
- Cerebral arteritis 0 trials
-
Phlebitis 13 trials · 21 incl. sub-types
1 sub-type
- Thrombophlebitis 6 trials · 9 incl. sub-types Sub-types →
-
Immune complex mediated vasculitis 0 trials · 18 incl. sub-types
5 sub-types
- Immunoglobulin A vasculitis 16 trials
- Cryoglobulinemic vasculitis 4 trials Sub-types →
- Hypocomplementemic urticarial vasculitis 2 trials
- Cutaneous leukocytoclastic angiitis 1 trial
- Erythema elevatum diutinum 0 trials
-
Hypersensitivity vasculitis 0 trials · 16 incl. sub-types
2 sub-types
- Immunoglobulin A vasculitis 16 trials
- Allergic cutaneous vasculitis 1 trial
-
Kawasaki disease 15 trials
-
Cutaneous vasculitis 4 trials · 5 incl. sub-types
1 sub-type
- Allergic cutaneous vasculitis 1 trial
-
Deficiency of adenosine deaminase 2 3 trials
-
Retinal vasculitis 2 trials
-
Aortitis 1 trial
-
Livedoid vasculopathy 1 trial
-
Choroiditis 0 trials · 1 incl. sub-types
4 sub-types
- Serpiginous choroiditis 1 trial
- Infectious posterior uveitis 0 trials
- Multifocal choroiditis 0 trials Sub-types →
- Paraneoplastic uveitis 0 trials
-
Secondary vasculitis 0 trials · 1 incl. sub-types
2 sub-types
- Drug-induced vasculitis 1 trial
- Postinfectious vasculitis 0 trials
-
Shwartzman phenomenon 0 trials
-
Autoimmune vasculitis 0 trials
1 sub-type
- Rheumatoid vasculitis 0 trials
-
Lymphangitis 0 trials
-
Vasculitis, lymphocytic, nodular 0 trials
Most studied deeper sub-types
-
Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term
Disease control CompletedThis study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by review…
Sponsor: European EGPA Study Group • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a simple shield keep IVs in place longer for cancer patients?
Disease control CompletedThis trial tests whether a special catheter protector, called I.V. House UltraDressing, can help peripheral IV catheters stay in place longer and cause fewer complications in adult cancer patients. Participants are randomly assigned to receive either the standard transparent dres…
Sponsor: Karamanoğlu Mehmetbey University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Steroid showdown: can a tiny daily dose keep a rare disease at bay?
Disease control CompletedThis study looked at 159 people with granulomatosis with polyangiitis (GPA), a rare disease that causes inflammation of blood vessels. Participants were randomly assigned to either stay on a low 5 mg daily dose of prednisone or slowly stop it over six months. The goal was to see …
Phase 3 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a blood vessel drug reverse sudden blindness in giant cell arteritis?
Disease control CompletedThis trial investigates whether bosentan, a drug that blocks endothelin and relaxes blood vessels, can help people who suddenly lose vision from giant cell arteritis (Horton's disease). Standard steroid treatment often fails to restore sight once blindness occurs. The study enrol…
Phase 3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to tame rare blood vessel disease
Disease control CompletedThis study tested whether adding rituximab to standard steroid treatment helps adults with IgA vasculitis (a disease causing inflamed blood vessels) achieve remission without needing steroids long-term. 75 participants with new or relapsing disease were randomly assigned to recei…
Phase 3 • Sponsor: Hopital Foch • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Which bypass works best? synthetic tube vs. your own vein
Disease control CompletedThis study looked at 100 people with severe leg artery disease (including some with diabetes) who needed bypass surgery above the knee. Doctors compared using a man-made tube (Dacron or PTFE) versus the patient's own leg vein to reroute blood flow. The goal was to see which metho…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New bandage for IVs could slash infection risk
Disease control CompletedThis study tested a special bandage (dressing) that contains a germ-killing ingredient called chlorhexidine for IV tubes placed in the arm. The goal was to see if it reduces infections and other complications compared to the standard bandage. About 300 patients in Australia and F…
Sponsor: The University of Queensland • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Small study tests rituximab against rare vessel disease
Disease control CompletedThis study tested whether the drug rituximab, given with steroids, works better than steroids alone for people with a rare disease called microscopic polyangiitis that inflames small blood vessels. Only 8 patients took part, and the goal was to see if the combination could preven…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Heart-Saving combo: steroid plus standard therapy may shield kids from kawasaki damage
Disease control CompletedThis study looked at whether adding a steroid called prednisolone to the usual treatment (immunoglobulin and aspirin) could reduce heart artery damage in children with Kawasaki disease. Over 3,200 children took part. The goal was to see if the combination therapy lowers the chanc…
Phase 3 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental IL-2 treatment shows promise for Hard-to-Treat HCV vasculitis
Disease control CompletedThis study tested a drug called interleukin-2 (IL-2) in 10 people with hepatitis C-related vasculitis that did not get better with usual treatments. The goal was to see if IL-2 could boost the body's immune regulation and control the disease. Participants received IL-2 injections…
Phase 1/2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug aims to tame giant cell arteritis with fewer steroids
Disease control CompletedThis phase 3 trial tested secukinumab, a biologic drug, in 354 people with giant cell arteritis (GCA), a condition causing inflamed arteries. Participants received either secukinumab or a placebo, along with a steroid taper. The goal was to see if secukinumab could help more peop…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for rare artery disease? small trial tests upadacitinib
Disease control CompletedThis completed study tested the drug upadacitinib in 12 people with refractory Takayasu arteritis, a rare autoimmune disease that inflames the body's largest artery. The goal was to see if the drug could help patients who haven't responded to standard treatments achieve remission…
Sponsor: Liu Tian • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New IV treatment explored for painful inflammatory conditions
Disease control CompletedThis study looked at how an intravenous (IV) form of secukinumab is processed by the body and whether it is safe for adults with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR). These conditions cause inflammation in blood vessels or muscles, leading to pain and stiffn…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug aims to tame blood vessel inflammation without steroids
Disease control CompletedThis study tested the drug secukinumab (Cosentyx) in 151 adults with newly diagnosed giant cell arteritis, a condition causing inflamed blood vessels. Participants were in remission and received either secukinumab or a placebo, along with a steroid taper. The goal was to see if s…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill could tame blood vessel inflammation
Disease control CompletedThis study tested the drug upadacitinib (RINVOQ) in 429 people with giant cell arteritis, a condition causing inflamed blood vessels. Participants took the drug or a placebo along with steroids. The goal was to see if upadacitinib helps achieve remission faster and with less ster…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to stop heart damage in kids with kawasaki disease
Disease control CompletedThis early-phase study tested a combination of atorvastatin and anakinra in 5 children with Kawasaki disease who had coronary artery abnormalities. The goal was to see if these drugs could safely reduce artery inflammation and prevent future heart problems. The study focused on s…
Early phase 1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study tracks Nucala's Long-Term impact on rare inflammatory disease
Disease control CompletedThis study followed about 300 people with EGPA (a rare disease causing inflammation in blood vessels) who were treated with Nucala injections for up to 2 years. Researchers monitored side effects, how well the drug controlled symptoms, and how long it took for the disease to flar…
Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Real-World FASENRA study completed in korea: safety under the microscope
Disease control CompletedThis completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during rou…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug MT-2990 tested in rare blood vessel disease
Disease control CompletedThis early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…
Phase 1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for EGPA: rituximab shows promise in major trial
Disease control CompletedThis study tested whether the drug rituximab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) achieve remission better than standard treatments. 107 adults with active EGPA were randomly assigned to receive either rituximab or conven…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for kids with stubborn kawasaki disease: drug targets fever and heart risks
Disease control CompletedThis study tested a drug called TA-650 in 31 children with Kawasaki disease whose fever did not go away after standard IVIG treatment. The goal was to see if TA-650 could bring down the fever faster and prevent damage to heart arteries compared to another immunoglobulin treatment…
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New Clot-Busting device tested in hong kong
Disease control CompletedThis study tested a device called the JETi system to remove blood clots from veins or arteries in the arms or legs. It included 12 adults of Asian descent in Hong Kong. The goal was to see how well the device cleared clots and if it caused serious side effects like bleeding or re…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Cheaper rituximab versions just as safe and effective for rare vasculitis?
Disease control CompletedThis study looked at 201 Canadian patients with ANCA-associated vasculitis to see if cheaper biosimilar versions of rituximab work as well as the original drug. Researchers compared disease control, side effects, and how long it took to get insurance approval for treatment. The g…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Statin trial targets hidden heart risk in vasculitis patients
Disease control CompletedThis study tested whether rosuvastatin, a common cholesterol-lowering drug, could reduce early signs of artery hardening in 121 people with ANCA-associated vasculitis. Participants were in remission and received either rosuvastatin or a placebo for up to 2 years. The goal was to …
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a Double-Dose vaccine strategy shield vulnerable vasculitis patients?
Disease control CompletedThis study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can flu shots protect autoimmune patients?
Disease control CompletedThis study looked at how well flu vaccines (seasonal and H1N1) work in 234 adults with autoimmune diseases like lupus or vasculitis, some of whom were on steroids or immunosuppressants. Researchers measured antibody levels three weeks after each shot to see if the vaccine provide…
Phase 4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Rituximab vs. azathioprine: which drug better prevents EGPA flares?
Disease control CompletedThis study tested whether rituximab (given as an infusion every 6 months) is better than azathioprine (daily pills) at keeping eosinophilic granulomatosis with polyangiitis (EGPA) in remission. 98 adults with newly diagnosed or relapsing EGPA who had already achieved remission to…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Rituximab shows promise in preventing vasculitis relapses
Disease control CompletedThis study tested whether rituximab, a targeted antibody therapy, is better than azathioprine, a standard immune-suppressing drug, at preventing relapses in people with ANCA-associated vasculitis. 117 patients who had achieved remission were randomly assigned to receive either ri…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can extra rituximab keep vasculitis at bay?
Disease control CompletedThis study looked at whether giving rituximab for 46 months instead of the usual 18 months can better prevent relapses of ANCA-associated vasculitis, a rare autoimmune disease that causes blood vessel inflammation. 97 patients who were already in remission after initial rituximab…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for rare lung scarring? small trial tests pirfenidone
Disease control CompletedThis small pilot study looked at whether the drug pirfenidone is safe and effective for people with a specific type of lung scarring (pulmonary fibrosis) linked to MPO antibodies or vasculitis. Seven adults took the drug for a year, and researchers measured changes in lung functi…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can a modified vitamin a pill save sight in dry AMD?
Disease control CompletedThis study tests a daily pill called ALK-001, a modified form of vitamin A, to see if it can slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 300 people with the condition took either the drug or a place…
Phase 2/3 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy aims to tame rare blood vessel disease
Disease control CompletedThis study tested whether adding azathioprine to standard corticosteroid treatment helps people with certain types of vasculitis (blood vessel inflammation) achieve remission and avoid relapses. 114 newly diagnosed patients without poor prognosis factors took part. The goal was t…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
Psoriasis drug OTEZLA tested in everyday use
Disease control CompletedThis completed study observed over 1,000 people with psoriasis who were prescribed OTEZLA (apremilast) for the first time. Researchers tracked side effects, symptom improvement, and quality of life over several years. The goal was to see how well the drug works in real-world sett…
Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 14:49 UTC
-
Smart dosing of rituximab may keep rare blood vessel disease at bay
Disease control CompletedThis study tested two ways of giving rituximab to people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. All 166 participants were in remission and received rituximab either on a fixed schedule or only when certain blood markers (ANC…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 13:48 UTC
-
Chewing gum test may spot hidden jaw pain in Horton's disease
Diagnosis CompletedThis study tested whether chewing gum can help doctors diagnose giant cell arteritis (Horton's disease), a condition where blood vessels become inflamed. The idea is that chewing may trigger jaw pain in people with the disease, making it easier to spot. Researchers compared resul…
Sponsor: University Hospital, Limoges • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New scan could replace needle biopsy for artery disease diagnosis
Diagnosis CompletedThis study looked at whether a PET/CT scan of the head arteries can accurately diagnose giant cell arteritis, a type of blood vessel inflammation. Researchers compared the scan results to those from ultrasound and MRI in 70 patients suspected of having the condition. The goal was…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
Pocket-Sized ultrasound could cut unnecessary tests at the Doctor's office
Diagnosis CompletedThis study looked at whether giving family doctors a small, portable ultrasound machine helps them diagnose and manage eight common conditions (like pneumonia, kidney stones, and pregnancy issues) without needing extra tests. Over 160 patients took part, and researchers compared …
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Two-Minute sweat test could spot hidden nerve damage
Diagnosis CompletedThis study tested a device called SUDOSCAN, which measures sweat function in just two minutes, to see if it can detect small fiber nerve damage in people with autoimmune diseases (like lupus or rheumatoid arthritis) or unexplained pain. Researchers enrolled 139 adults and compare…
Sponsor: Hôpital Européen Marseille • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
New digital PET/CT could spot hidden artery inflammation and prevent blindness
Diagnosis CompletedGiant cell arteritis (GCA) causes inflamed arteries and can lead to blindness if not treated quickly. This study tested a new digital PET/CT scan that can see tiny arteries in the head, which older scans missed. 92 patients with suspected GCA got both a PET/CT and an ultrasound. …
Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 13:06 UTC
-
New care bundle slashes IV complications in kids at ER
Prevention CompletedThis study tested a care bundle—a set of steps including nurse training, hand washing, and special cleaning solutions—to prevent IV-related problems like swelling and vein inflammation in children. Researchers compared 200 kids in the emergency department who either got the care …
Sponsor: Istanbul University - Cerrahpasa • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New sticky patch aims to make IV catheters safer and less painful
Symptom relief CompletedThis study tests a special adhesive patch made with zinc oxide to hold catheters (thin tubes placed in veins) in place for hospitalized adults. The goal is to see if it reduces complications like the catheter moving, skin irritation, vein swelling, and pain. About 400 patients wh…
Sponsor: Hospital Arnau de Vilanova • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Ice packs put to the test against painful antibiotic injections
Symptom relief CompletedResearchers are testing whether applying ice around an intravenous catheter before an oxacillin injection can lower pain and reduce peripheral phlebitis, an inflammation of the vein. The trial enrolls 86 hospitalized adults aged 20 to 60 who receive oxacillin through a hand vein.…
Sponsor: Central Taiwan University of Science and Technology • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Music as medicine: simple tunes may soothe wound pain in artery disease
Symptom relief CompletedThis study tested whether listening to music during wound dressing changes can reduce pain in people with severe arteritis (stage 5 or 6). Twenty-five patients were asked to listen to music during their daily wound care. The main goal was to see if pain levels were lower on a 0-1…
Sponsor: University Hospital, Limoges • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a drug shrink nasal polyps in rare disease patients?
Symptom relief CompletedThis study looked at 52 adults with EGPA (a rare inflammatory disease) and severe chronic sinusitis with nasal polyps. They received mepolizumab 300 mg every 4 weeks. The goal was to see if the drug reduces polyp size and improves symptoms like nasal congestion and sense of smell…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Could a tiny dose of naltrexone ease vasculitis symptoms?
Symptom relief CompletedThis study tested whether a low dose (4.5 mg) of naltrexone, a drug already used for alcoholism, can improve physical health and quality of life in people with vasculitis. Sixty participants took either the drug or a placebo daily for six weeks. The goal was to see if the drug le…
Phase 2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
COVID-19's hidden toll on autoimmune patients revealed
Knowledge-focused CompletedThis study followed 293 people with autoimmune diseases and healthy volunteers to see how COVID-19 infection or vaccination affects their immune system, inflammation, and blood vessels. Participants were grouped based on their COVID-19 history and had up to 5 visits over 12-18 mo…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a vaccine test expose hidden immune weakness?
Knowledge-focused CompletedThis trial tests whether rituximab, a drug used for ANCA-associated vasculitis, leaves patients with a weakened immune system. Researchers give pneumococcal vaccines to patients treated with rituximab, patients with the disease but not on rituximab, and healthy volunteers. They c…
Phase 2 • Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
A blood clue to a rare vessel disease?
Knowledge-focused CompletedThis study looks at whether a protein in the blood, called soluble CD95 ligand, plays a role in ANCA-associated vasculitis, a rare group of diseases that cause inflammation of blood vessels. Researchers will collect blood and urine samples from 48 adults with the condition and tr…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
PET scans could revolutionize monitoring of rare inflammatory disease
Knowledge-focused CompletedThis study explores whether a special type of PET/CT scan, using a radioactive tracer called 18F-FDG, can accurately measure disease activity in people with granulomatosis with polyangiitis (GPA), a rare condition that causes inflammation of blood vessels. Researchers will compar…
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Rare artery disease linked to higher heart attack and stroke risk
Knowledge-focused CompletedThis study uses French national health data to compare the risk of major heart problems—like heart attack, stroke, and death—in people with Takayasu arteritis versus similar people without the disease. It also looks at how steroid use may affect these risks. The goal is to better…
Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Scientists hunt for clues to diagnose rare inflammatory diseases
Knowledge-focused CompletedThis completed study reviewed the medical records of 210 people with aortitis (inflammation of the aorta) or retroperitoneal fibrosis (scar tissue in the abdomen). The goal was to find patterns in symptoms, lab tests, and imaging that could help doctors tell different types of th…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive study reveals hidden dangers of common steroid treatments
Knowledge-focused CompletedThis completed study looked at over 107,000 patients in Germany to understand the long-term side effects of systemic steroids (corticosteroids) used for conditions like asthma, COPD, and arthritis. Researchers compared patients who took steroids with those who did not, tracking r…
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study links common arthritis treatments to diabetes risk
Knowledge-focused CompletedThis observational study followed 198 adults aged 50–85 with giant cell arteritis or polymyalgia rheumatica to understand how common treatments (glucocorticoids and interleukin-6 inhibitors) affect diabetes risk. Researchers tracked blood sugar levels and other markers over time.…
Sponsor: Salome Kristensen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Stitch showdown: which cesarean closure method lowers niche risk?
Knowledge-focused CompletedThis study looked at 366 women having their first planned cesarean section to see if closing the uterine incision with one layer of stitches or two layers affects the chance of developing a uterine niche (a small pocket in the scar). Participants were asked about symptoms like sp…
Sponsor: Kafrelsheikh University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Kawasaki Kids' hearts under the microscope 5 years later
Knowledge-focused CompletedThis study looked at the heart health of 61 children who had Kawasaki disease 5 years earlier and were treated with IVIG. Researchers compared them to healthy children using blood tests, blood pressure, artery stiffness, and heart imaging. The goal was to find early signs of hear…
Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists probe immune cell clues in rare disease
Knowledge-focused CompletedThis study looked at immune cells from 138 people with Wegener's granulomatosis, a rare disease causing inflammation of blood vessels. Researchers measured levels of a protein called DAP12 in different immune cells to understand how the disease works. No new treatment was tested;…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Nurses' insights could transform phlebitis care in ICUs
Knowledge-focused CompletedThis study explores the experiences of 20 intensive care nurses in managing phlebitis, a painful vein inflammation often caused by IV lines. Through face-to-face interviews, researchers aim to uncover common challenges and helpful strategies. The goal is to improve prevention and…
Sponsor: Kutahya Health Sciences University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scientists investigate immune cells in Horton's disease
Knowledge-focused CompletedThis study looked at whether a type of immune cell called T CD8 plays a role in Horton's disease, a condition that causes inflammation in blood vessels. Researchers took extra blood samples and performed standard tests on 30 newly diagnosed patients to measure these immune cells.…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Which drug protects the heart better in giant cell arteritis?
Knowledge-focused CompletedThis study looked at over 1,600 people with giant cell arteritis, a condition that inflames blood vessels and raises heart risks. Researchers compared tocilizumab and methotrexate to see which better prevents heart attacks, strokes, or death. Using French health data, they analyz…
Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
IV catheter showdown: which type stays put longer in the ICU?
Knowledge-focused CompletedThis study compared two types of IV catheters—closed and open—in 100 patients in a respiratory intensive care unit. The goal was to see which type stays functional longer without complications like thrombophlebitis. Researchers measured dwell time and catheter-related issues to f…
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Scientists investigate immune cell defects in rare blood vessel disease
Knowledge-focused CompletedThis study looked at blood samples from 41 people with giant cell arteritis (Horton's disease), a condition that causes inflammation in blood vessels. Researchers examined specific immune cells called regulatory T cells to see if they are defective in this disease. The goal is to…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Lockdown diaries: 1,300 patients reveal hidden health risks
Knowledge-focused CompletedThis study looked at how the COVID-19 lockdown changed the health habits and medical care of 1,343 people with chronic conditions like heart disease, multiple sclerosis, and hemophilia. Researchers used phone surveys to track medication use, lifestyle changes, and access to healt…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Blood filter showdown: which method clears harmful antibodies faster?
Knowledge-focused CompletedThis study compares two blood-filtering techniques—plasma exchange and immunoadsorption—in 40 patients with severe kidney failure caused by ANCA vasculitis or Goodpasture disease. The goal is to see which method removes disease-causing antibodies more quickly. Results may help do…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a computer help doctors choose the right blood thinner?
Knowledge-focused CompletedThis study tested a decision-support tool called DOACT that helps doctors choose the right blood thinner for patients with blood clots in veins or lungs. Researchers compared how well the tool performed against artificial intelligence models and doctors' own judgment. The goal wa…
Sponsor: ITALO EUGENIO SOUZA GADELHA DE ABREU • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Study reveals gaps in Follow-Up care for kids with rheumatoid purpura
Knowledge-focused CompletedThis study observed 66 children diagnosed with rheumatoid purpura in three French hospital emergency rooms. Researchers tracked how well doctors followed official care guidelines and surveyed family doctors about their knowledge of the condition. The goal was to identify obstacle…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Immune cell study sheds light on childhood disease
Knowledge-focused CompletedThis study examined blood samples from 100 children with Henoch Schönlein Purpura (HSP) and a control group to see if regulatory T cells (Tregs) are missing or not working properly. The goal was to learn more about the disease, not to test a new treatment. Researchers measured Tr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Massive eye drug study reveals rare inflammation risk
Knowledge-focused CompletedThis study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the s…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Massive Real-World study investigates rare eye inflammation after common injection
Knowledge-focused CompletedThis completed study analyzed data from nearly 290,000 patients who received aflibercept (Eylea) injections for various retinal diseases. The goal was to estimate how often retinal vasculitis (inflammation of blood vessels in the eye) occurs in real-world clinical practice. Resea…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New monitoring methods aim to prevent paralysis after aortic surgery
Knowledge-focused CompletedThis study tests two new monitoring techniques—long loop reflexes (F-waves) and near-infrared spectroscopy (NIRS)—to detect spinal cord ischemia early after thoracoabdominal aortic aneurysm repair. Current methods work during surgery but are too painful for awake patients afterwa…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Scientists probe immune cells to unlock vasculitis mysteries
Knowledge-focused CompletedThis study looked at how certain immune cells, called neutrophils, behave in people with granulomatosis with polyangiitis (GPA), a rare blood vessel inflammation disease. Researchers collected blood samples from 93 participants, including patients with GPA and other related condi…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:35 UTC
-
Surgery may boost survival in rare artery disease
Knowledge-focused CompletedThis study looked at 78 people with Takayasu arteritis, a rare disease that causes narrowing of the main artery from the heart. Researchers compared those who had surgery or a procedure to open the artery with those who got only medication. The goal was to see which group lived l…
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:45 UTC